K R Aigner1, S Gailhofer, S Kopp. 1. Asklepios Paulinen Klinik, Abteilung fur Chirurgische Onkologie, Wiesbaden, Germany.
Abstract
BACKGROUND/AIMS: In an attempt to improve treatment protocols for advanced pancreatic cancer, the value of regional chemotherapy compared with systemic chemotherapy was investigated in this randomized study. METHODOLOGY:Fourteen patients with advanced non-resectable pancreatic adenocarcinoma were randomized receiving either systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5pts.) orceliac axis infusion regional chemotherapy with SpherexR microembolization. In the systemic group one patient was stage III, four patients were stage IV, in the intraarterial group two patients were specified stage III and seven were stage IV. RESULTS: In the systemic group one stable disease and four progressive diseases were noted, in the regional group two stable diseases and seven partial responses were noted. Median survival was 11 weeks in the systemically treated patients versus 33 weeks in the patients treated with intraarterial infusion (p=0.001). One patient became resectable (R0). CONCLUSIONS:Performance status improved during regional chemotherapy whilst it steadily decreased in the patients treated systemically. The study was terminated at that point.
RCT Entities:
BACKGROUND/AIMS: In an attempt to improve treatment protocols for advanced pancreatic cancer, the value of regional chemotherapy compared with systemic chemotherapy was investigated in this randomized study. METHODOLOGY: Fourteen patients with advanced non-resectable pancreatic adenocarcinoma were randomized receiving either systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5pts.) or celiac axis infusion regional chemotherapy with SpherexR microembolization. In the systemic group one patient was stage III, four patients were stage IV, in the intraarterial group two patients were specified stage III and seven were stage IV. RESULTS: In the systemic group one stable disease and four progressive diseases were noted, in the regional group two stable diseases and seven partial responses were noted. Median survival was 11 weeks in the systemically treated patients versus 33 weeks in the patients treated with intraarterial infusion (p=0.001). One patient became resectable (R0). CONCLUSIONS: Performance status improved during regional chemotherapy whilst it steadily decreased in the patients treated systemically. The study was terminated at that point.
Authors: Twan Lammers; Peter Peschke; Rainer Kühnlein; Vladimir Subr; Karel Ulbrich; Peter Huber; Wim Hennink; Gert Storm Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Ali I Shamseddine; Mohammad J Khalifeh; Fadi H Mourad; Aref A Chehal; Aghiad Al-Kutoubi; Jaber Abbas; Mohammad Z Habbal; Lida A Malaeb; Anwar B Bikhazi Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: Asma Sultana; Susannah Shore; Michael Gt Raraty; Sobhan Vinjamuri; Jonathan E Evans; Catrin Tudur Smith; Steven Lane; Seema Chauhan; Lorraine Bosonnet; Conall Garvey; Robert Sutton; John P Neoptolemos; Paula Ghaneh Journal: BMC Cancer Date: 2009-02-25 Impact factor: 4.430